This is a summary of the European public assessment report (EPAR) for Ecalta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ecalta.
For practical information about using Ecalta, patients should read the package leaflet or contact their doctor or pharmacist.
Ecalta : EPAR - Summary for the public (PDF/85.09 KB)
First published: 05/11/2009
Last updated: 27/10/2014
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Europe MA EEIG
|Date of issue of marketing authorisation valid throughout the European Union||
26/09/2018 Ecalta - EMEA/H/C/000788 - T/0037
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of invasive candidiasis in adult non-neutropenic patients.
Ecalta has been studied primarily in patients with candidaemia and only in a limited number of patients with deep tissue Candida infections or with abscess-forming disease.